预约演示
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
2023-02-03
高管变更引进/卖出
None
Welcome to this week's (and last week's) Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
Ginkgo BioWorks CEO, ex-Google head plucked for federal biotech commission
The National Security Commission on Emerging Biotechnology
Ginkgo BioWorks.D." dataGoogley-type="media" data-entity-uuid="b9d35093-2066-4612-a7f0-0b58a7121e90" data-view-mode="thumbnail"/>
Ginkgo BioWorks CEO and co-founder Jason Kelly, Ph.D., has been selected to lead a 12-member group assessing emerging biotech innovation for the U.S. Department of Defense. The commission’s main focus will be reviewing how biotech advancements and related tech can help shape department activities. After one year, the commission is meant to produce an interim report for the U.S. President Joe Biden and the Armed Services Committees. The end goal is providing a final, unclassified report within two years, including recommendations for action by Congress and the federal government.
Michelle Rozo, Ph.D., was chosen to serve as vice chair for the commission. She was previously Director of Technology and National Security at the National Security Council, where she advised the president on biotech and national security policy.
Ginkgo BioWorksPh.D." data-entity-type="media" data-entity-uuid="15f828a0-0f52-444f-973b-88ad44986a36" data-view-mode="thumbnail"/>U.S. Department of Defense
Google’s former CEO Eric Schmidt, Ph.D., who serves as a strategic adviser and founding nonmanaging partner for VC First Spark Ventures, has also been appointed to the commission. However, members of the newly formed group don’t have to divest their own personal biotech investments, which could potentially allow members to profit if their companies receive new federal biotech spending, according to a CNBC report.
The other appointed commissioners are: national security expert Paul Arcangeli; Oklahoma's 5th Congressional District Representative Stephanie Bice; materials scientist and biological engineer Angela Belcher, Ph.D.; California’s 17th Congressional District Representative Ro Khanna; former CIA executive Dawn Meyerriecks; California Senator Alex Padilla; former Assistant Director for Biotechnology in the Office of the Under Secretary of Defense for Research & Engineering Alexander Titus, Ph.D.; Indiana Senator Todd Young; and senior adviser and defense expert Dov Zakheim, Ph.D. Release
Googleec set to depart this summer
Bristol Myers Squibb
Rupert Vessey" data-entity-type="media" data-entity-uuid="3ecc2787-2c8e-4c86-b1df-8767a66b9d2f" data-view-mode="half_body_width"/>
Bristol Myers Squibbame into the Bristol Myers Squibb orbit with the 2019 acquisition of Celgene, is set to retire effective July 3.
BMS CEO Giovanni Caforio, M.D., announced the departure at the top of the company’s fourth-quarter earnings call Thursday.
Vessey is executive vice presidenBristol Myers Squibbesearch and early development. He joCelgenelgene in 2015, serving as president of the research and early development organization. Prior to that, he held roles at Merck & Co. and GSK.
BMSpert led the successful integration of research and the development of a strong pipeline across all stages of development,” Caforio said.
Vessey’s name has cropped up in a number of BMS’ recent transactions, including the $905 milliCelgenensing deal with BridgeBio and the third collaboration with immunotherapy drug discovery biotech Immatics that couldMerck & Co.s mucGSKs $4.2 billion down the line.
Taking over for Vessey as executive vice president and chief research officer will be Robert Plenge, M.D., Ph.D., who has served as head of the Immunology, Cardiovascular and Fibrosis Thematic Research Center and head of translational medicine. Webcast
RocheFibrosis
Rochea Graham" data-entity-type="media" data-entity-uuid="836c9051-cb50-4305-9974-923dc6e537f7" data-view-mode="thumbnail"/>
Rocheig Pharma is mixing up its leadership team, selecting current Head of Global Product Strategy Teresa Graham to helm Roche’s pharma group as CEO. Starting next month, Graham will replace Thomas Schinecker, who has served as interim leader since Bill Anderson’s departure at the end of 2022. For his part, Schinecker is set to become CEO of the entire Roche group this March.
Graham has been with Roche for nearly four years and will take over as COVID product sales across pharma and diagnostics drop due to declining demand. Before Roche, Graham spent more than 14 years at Genentech until the company was acquired by Roche.
> T-cell therapy compRochelueSphere Bio has tapped former Takeda exec Erkut Bahceci, M.D., to serve as the company’s chief medical officer. Before serving as Rochea’s SVP and head of oncology developmGenentechorked at Astellas for a decade in rRocheof increasing responsibility up to the head of clinical science of hematologic malignancies. Before Astellas, Bahceci worked at Bristol Myers Squibb and Bayer. Release
> Wilson Bryan, M.Rochehe FDA’s director of the office of tissues and advanced therapies at the Center for Biologics Evaluation and Research, will be retiring in March of this year, the FDA confirmed with Fierce Biotech.
> Texas-based Taysha GeneBlueSphere Bioparting with anotheTakedautive, this time the company’s chief medical officer Suyash Prasad. Prasad’s exit came only a Takedar so after RA Session II resigned, though Session stilAstellason to his founder and board member titles. Before Taysha, Prasad held roles at BioMarin Phhematologic malignanciesnd Eli LiAstellasng others. ReleaseBristol Myers SquibbBayer
> Merck’s Joseph Eid, M.D.FDAas left the Big Pharma for biotech, joining Dragonfly Therapeutics Center for Biologics Evaluation and Researched lead the development of pembrolizumab, alsoFDAown as Keytruda. Before Merck, Eid also worked at BMS and Roche. Release
> Nadège PelleTaysha Gene Therapiestaking the chief scientific officer reins from Tom Evans, Ph.D., at Vaccitech. Evans is retiring after six years with the clinical-stage company. As for Pelletier, she joins from the Novartis Institutes for Biomedical Research and has also worked at Roche in its researcBioMarin PharmaceuticalsarGenzymeaseEli Lilly
> Merck D’Amour, Ph.D., has joined Stemson Therapeutics as the cell theraDragonfly Therapeuticsentific officer. Before joiningMerckson, D’Amour spent nearly two decadepembrolizumab which was acquiKeytrudaertex in Merck ReleaseBMSRoche
> Starting April 1, Anton (Tony) HoStemson Therapeuticsl head up R&D and medical affairs and also serve as chief medical officeStemsonwedish Orphan Biovitrum (Sobi). Hoos wViaCytelace Anders Ullman, M.D.Vertex. who is set to retire. The incoming CMO carries more than three decades of industry experience, including positions at Amgen, GSK and Aventis. Release
> Athira Pharmama has started the hunt for a new chief scientific officer after CSO and Chief Operating Officer Christian Kjellman announced plans to leave in 20neurodegeneration diseases the company since 2008, taking on the dual leadership role in 2020. Release
> Oncology biotech Ariceum Therapeutics has brought on Germo Gericke, M.D., to serve as the company’s chief medical officer. Germo joSwedish Orphan Biovitrumced Accelerator Applications, where he held positions of chief medical officer and head of R&D. ReleaseAmgenGSKAventis
> Hansa Biopharmas is welcoming Elizabeth Keiley as EVP and general counsel. She most recently served as general counsel for Entasis Therapeutics. Before that, she also held leadership positions at Oxford Immunotec and Zimmer. Release
> Will Kane is leavAriceum Therapeuticsand chief commercial officer at BioXcel Therapeutics for Karuna Therapeutics, a clinical-stage company Novartiso develop medicines for psychiatric and neurological conditions. Kane will take on the role starting Feb. 6. The leader has held senior level commercial positions at Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals) and helped launch several successful brands including Namzaric for Alzheimer’s disease, Vraylar for schizophrenia and bipolar disorder, and Ubrelvy for migraines. Release
> vTv Therapeuticss has called on Christopher Wright, M.D., Ph.D., to serve as chief medical officer and head of translationaEntasis Therapeutics Feb. 7. Before Ring, Wright was CMO at AavantiBio, wOxford Immunotecy acquired by Solid Biosciences. He has also held leadership roles at Cyclerion, Ironwood Pharmaceuticals, Axcella Health and Vertex Pharmaceuticals. Release
> Clinical-stage Adrenomed has tapped Stephan Witte, M.D., to serve as BioXcel TherapeuticsmedicKaruna TherapeuticsAdrenomed, Witte was VP of clinical science and operations at Atriva Therapeutics and has also held positions at Breath Therapeutics, Inotrem and Helion Pharma. ReleaseAllerganPfizerSepracorSunovion PharmaceuticalsAlzheimer’s diseaseVraylarschizophreniabipolar disorderUbrelvymigraines
> Ring Therapeuticsas appointed Sandra Aung, Ph.D., to serve as the company’s EVP and head of clinical development. Aung most recently served as OncoSec’s SVP and has years of experiencAavantiBioate Therapeutics, HUYA BioscienceSolid Biosciencesektar Therapeutics, Prometheus LaboratoCyclerionVaIronwood Pharmaceuticalsg Axcella HealtheVertex Pharmaceuticals
> Roger Sidhu, M.Adrenomedopped aboard Treadwell Therapeutics, joining the team as chief medical officer. Sidhu wasAdrenomedently CMO at Brooklyn (now Eterna) ImmunoTherapeuticsAtriva Therapeuticsroles at Roivant Sciences, Cell Breath TherapeuticsedInotremead subsidiary Kite) and Amgen. Release
> Ambrx Biopharmaer founding Know Labs—then known as Visualant—Ron Erickson is once again stepping into the role of CEO. He’s replacing Phil BosuOncoSechad served as CEO of the tech developer siFate TherapeuticshoHUYA Bioscience International sNektar TherapeuticschPrometheus LaboratoriesulUbiVacAs foCell Genesyshe helmed Know Labs between 2003 and 2004 and took on the top job once again at the end of 2009 until Bosua replaced him. The company also announced a handful of other executive changes, including Masanori King Takee, who has been at Know Labs since 2018, was named chief technology officer. Leo Trautwein, meanwhile, is transitioning from his previous title of chief marketing officer to serve as chief commercial officer. He’s been replaced as marketing head by Jessica English, previously the VP of brand at health-tracking ring maker Oura. Fierce Biotech
> Clinical-stage biotech TC BioPharm haTreadwell Therapeutics serve as chief clinical officer. Harlin most recently worked at Eli Lilly’s Loxo OncologyEternae ImmunoTherapeuticse clinical development of taRoivant Sciences fCell Design Labs of solid and Gilead subsidiaryrKiteeleaseAmgen
> Aprea Therapeutics’ forTC BioPharmnt and CEO Christian Schade has joined Flagship Pioneering as a growth partner to help scaEliaLillyow Loxo Oncologyded companies. Releasesolid and hematologic cancers
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。